Clinical Trials Directory

Trials / Completed

CompletedNCT00034918

This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer

An Open-label, Multicenter Phase II Study to Assess the Response of Subjects With Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy With or Without Capecitabine to ZD6474 (100-mg or 300-mg Daily Oral Dose).

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
44 (planned)
Sponsor
Genzyme, a Sanofi Company · Industry
Sex
Female
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to assess the efficacy of ZD6474 in patients with metastatic breast cancer at 2 dose levels.

Conditions

Interventions

TypeNameDescription
DRUGZD6474

Timeline

Start date
2002-05-01
Completion
2003-11-01
First posted
2002-05-03
Last updated
2016-08-24

Locations

2 sites across 2 countries: United States, Spain

Source: ClinicalTrials.gov record NCT00034918. Inclusion in this directory is not an endorsement.